Bain Capital Life Sciences Investors, LLC

Person Signing this Report on Behalf of Reporting Manager:

Bain Capital Life Sciences Investors, LLC ("BCLSI") is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the general partner of BC SW, LP, (iii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general partner of Bain Capital Life Sciences Fund II, L.P., which is the manager of BCLS II Investco (GP), LLC, which is the general partner of BCLS II Investco, LP, and (iv) the manager of Bain Capital Life Sciences III General Partner, LLC, which is the general partner of Bain Capital Life Sciences Fund III, L.P., which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC, which is the general partner of Bain Capital Life Sciences Opportunities III, LP. The shares of Annexon Inc. ("ANNX") include an aggregate of 3,514,418 shares of ANNX common stock issuable upon conversion of warrants and pre-funded warrants. As of 9/30/24, affiliates of BCLSI held 4,935,330 shares of ANNX common stock. The shares of Savara Inc. ("SVRA") are as reported on the Schedule 13D filed by affiliates of BCLSI on 4/12/24 and reflect the exercise of securities held by such persons for SVRA common stock, after giving effect to provisions that prevent exercise if such persons would beneficially own more than 9.99% of the SVRA common stock. As of 9/30/24, such persons held 12,162,552 shares of SVRA common stock. The shares of Syros Pharmaceuticals, Inc. ("SYRS") are as reported on the Schedule 13G filed by affiliates of BCLSI on 11/14/24 and reflect the exercise of securities held by such persons for SYRS common stock, after giving effect to provisions that prevent exercise if such persons would beneficially own more than 9.99% of SYRS common stock. As of 9/30/24, such persons held 2,030,857 shares of SYRS common stock. The shares of X4 Pharmaceuticals, Inc. ("XFOR") are as reported on the Schedule 13G filed by affiliates of BCLSI on 2/13/24 and reflect the exercise of securities held by such persons for XFOR common stock, after giving effect to provisions the prevent exercise if such persons would beneficially own more than 9.99% of XFOR common stock. As of 9/30/24, such persons held 14,879,809 shares of XFOR common stock. The shares of Dianthus Therapeutics, Inc. ("DNTH") reflect the exercise of securities held by affiliates of BCLSI for DNTH common stock, after giving effect to provisions that prevent exercise if such person would beneficially own more than 9.99% of DNTH common stock. As of 9/30/24, such persons held 2,197,638 shares of DNTH Common Stock. The shares of Xilio Therapeutics, Inc. ("XLO") are as reported on the Schedule 13G filed by affiliates of BCLSI on 11/14/24 and reflect the exercise of securities held by such persons for XLO common stock, after giving effect to provisions that prevent exercise if such persons would beneficially own more than 9.99% of XLO common stock. As of 9/30/24, such persons held 2,805,413 shares of XLO common stock.

Other Included Managers (11):